Fatty Liver Index May Misclassify Lean People With Metabolic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects millions worldwide and significantly impacts long-term health outcomes. While commonly associated with obesity, this condition can also occur in lean individuals, presenting unique diagnostic challenges that may compromise early detection and treatment.

Researchers from The Chinese University of Hong Kong investigated how the Fatty Liver Index (FLI), a widely-used screening tool, performs in identifying MASLD among lean populations. The FLI combines body mass index, waist circumference, and blood markers to assess fatty liver risk, but its accuracy across different body types remained unclear.

The study revealed significant limitations in current diagnostic approaches for lean individuals with MASLD. The researchers found that standard screening tools may systematically underdiagnose the condition in people with normal body weight, creating a substantial gap in clinical detection. This misclassification could delay crucial interventions that prevent progression to more severe liver disease.

For longevity and health optimization, these findings underscore the importance of personalized diagnostic approaches. Lean MASLD represents a distinct metabolic phenotype that may require different screening strategies and treatment protocols. Early detection remains critical, as untreated fatty liver disease can progress to cirrhosis and increase cardiovascular risk, significantly impacting healthspan.

The research highlights the need for healthcare providers to maintain clinical suspicion for MASLD even in lean patients, particularly those with metabolic risk factors. Future diagnostic tools should incorporate body composition variations to improve accuracy across all populations, ensuring that lean individuals receive appropriate screening and early intervention when necessary.